Form 4: Erin Lavelle Acquires Stock Options in Jade Biosciences, Inc.

Director Erin Lavelle reports acquisition of stock options in Jade Biosciences, Inc. on April 29, 2025.

Summary

• Erin Lavelle, a director of Jade Biosciences, Inc. (JBIO), filed a Form 4 on May 1, 2025, reporting a transaction.
• On April 29, 2025, Lavelle acquired options to purchase 23,017 shares of JBIO common stock at an exercise price of $10.14 per share.
• The options vest in full on the earlier of April 29, 2026, or the date of the next annual meeting of the Issuer's stockholders, subject to continued service to the Issuer.
• Following the transaction, Lavelle directly owns options for 23,017 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's acquisition could be seen as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of stock options by a director may positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, stock options, director, Jade Biosciences, JBIO, beneficial ownership, Erin Lavelle